8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Jan 12, 2026·SEC
Material company update
Jan 2, 2026·SEC
Vor Biopharma Inc.(VOR)Earnings, Financials & Key Ratios
VOR•NASDAQ
$20.10
Price updated Jul 6, 2026
AboutVor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$369M-213.4%
- Net Income-$696M-495.3%
- EPS (Diluted)-70.50-107.4%
VOR Price & Volume
Vor Biopharma Inc. (VOR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-Term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Execution Risk
Key Thesis Takeaways
- Vor Biopharma remains a high-risk, pre-revenue clinical-stage entity whose valuation is entirely tethered to the successful development of its hematopoietic stem cell platform.
- While the company maintains a cash position of $169.9 million as of 2026Q1, the persistent quarterly cash burn and negative equity position of -$150.4 million suggest significant future dilution risks.
- Investors should monitor the clinical progression of VOR33, as the lack of operating leverage and reliance on external capital markets remain primary threats to long-term viability.
Verdict Logic
the company's persistent cash burn and negative equity position of -$150.4 million indicate a high probability of future dilutive financing to sustain operations.
VOR Growth Metrics
Vor Biopharma Inc. (VOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-644.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2659.41%
Return on Capital
10 Years-406.8%
5 Years-68.57%
3 Years-86.84%
Last Year-131.97%
VOR Recent Earnings
Vor Biopharma Inc. (VOR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.73+2.7%
$0.75
Rev
—
—
Q2 2026
Apr 2, 2026Metric
Actual
Est
EPS
$82.04+7296.5%
$1.14
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$44.50+4003.5%
$1.14
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$3.33-8.8%
$3.06
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.73vs $0.75+2.7% | — |
| Q2 2026 | Apr 2, 2026 | $82.04vs $1.14+7296.5% | — |
| Q2 2026 | Mar 30, 2026 | $44.50vs $1.14+4003.5% | — |
| Q4 2025 | Nov 13, 2025 | $3.33vs $3.06-8.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Vor Biopharma Inc. (VOR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.10 | $137.76M | -0.29 | — | — | — | — | |
| $35.32 | $3.63B | -43.60 | 120.01% | -49.17% | -5.89% | — | |
| $61.89 | $5.97B | -9.57 | -89.97% | -13856.54% | -30.88% | — | |
| $3.65 | $357.36M | -2.03 | 25.39% | -281.59% | -677.39% | — | |
| $17.84 | $2B | -4.68 | 16.92% | -597.04% | -57.27% | — | |
| $2.99 | $348.51M | -2.60 | -51.24% | -2056.79% | -58.89% | — |
Compare VOR vs Peers
Vor Biopharma Inc. (VOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VOR SEC Filings & Documents
Vor Biopharma Inc. (VOR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VOR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VOR Frequently Asked Questions
Vor Biopharma Inc. (VOR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is VOR profitable?
Vor Biopharma Inc. (VOR) reported a net loss of $883.1M for fiscal year 2025.
Dividend & Returns
What is Vor Biopharma Inc.'s free cash flow?
Vor Biopharma Inc. (VOR) had negative free cash flow of $150.7M in fiscal year 2025, likely due to heavy capital investments.